Background
==========

Benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) is a common disease entity in older men and has a negative impact on quality of life (QoL) \[[@B1]-[@B3]\]. Obesity is also a common condition in older males and is related to LUTS \[[@B1],[@B3]\]. As in Western countries, Korean men have a high prevalence of symptomatic BPH as they age, with a prevalence of 10.6%--31% in men \> 50 years old \[[@B2],[@B4]\]. Several studies have reported a significant relationship between LUTS and obesity \[[@B3],[@B5],[@B6]\]. Considering the objective evidence of a negative effect of both LUTS \[[@B7]-[@B13]\] and obesity \[[@B14]\] on QoL, LUTS plus obesity may result in a greater deterioration of QoL.

Among the alpha blockers, tamsulosin is one of the most commonly recommended because of its efficacy, safety, and tolerability \[[@B15]\]. The King's Health Questionnaire (KHQ) is a validated tool to measure the QoL in patients with LUTS \[[@B9]\]. Although the KHQ was developed originally for female urge incontinence, validity has been proven in studies that dealt with LUTS and health-related quality of life (HRQoL) in both sexes \[[@B9],[@B16]-[@B19]\].

To date, efficacy of medical treatment among obese men with LUTS has been less clear, especially regarding the improvement of QoL within specific domains. Recently, Lee et al. \[[@B14]\] reported that alpha-blockers have a greater efficacy in improvement of LUTS when used in obese men. The main presumed hypothesis for this difference is that obese men have a greater level of sympathetic activity, which is suspected to be sensitive to alpha-blockers \[[@B20],[@B21]\].

The main purpose of this preliminary study is to investigate the improvement of LUTS and QoL in different groups (obese and non-obese).

Methods
=======

Study design
------------

An eight-week prospective study was conducted between March 2010 and May 2011. The study was approved by the institutional review board of Soonchunhyang University Hospital.

At the initial visit, anthropometric parameters were evaluated, including weight, height, and waist circumference. Additional parameters measured included urinalysis, serum prostate-specific antigen \[[@B22]\], maximal urinary flow rate (Qmax), and post-void residual volume (PVR). Transrectal ultrasonography was also performed. At the initial and final visits, the International Prostate Symptom Score (IPSS) and KHQ were measured.

BMI was calculated as the body weight in kilograms divided by the square of the height in meters. After the first evaluation, eligible patients were treated with tamsulosin at a dose of 0.4 mg for 8 weeks. At each visit, adverse events were recorded.

Serum PSA tests were performed using the automated chemiluminescent microparticle immunoassay analyzer Architect i2000 (Abbott Diagnostic Laboratories, Abbott Park, IL, USA). The prostate was measured in three dimensions by transrectal ultrasonography using an 8.0-MHz rectal probe (GE Healthcare, LOGIQ P6-PRO, Little Chalfont, UK), and prostate volume (PV) was estimated using a modification of the prolate ellipsoid formula and recorded in cm^3^ (0.523 \[length (cm) × width (cm) × height (cm)\]).

Acquisition of questionnaire data was performed with face-to-face interviews conducted by one investigator with all study participants using a structured questionnaire. The severity of LUTS was measured using the IPSS, which is based on the American Urological Association \[[@B23]\] symptom index with one additional question on QoL, and is the most widely used objective assessment of LUTS.

The KHQ consists of 8 categories, including general health perceptions, impact on life, role limitations, physical/social limitation, personal relationships, emotions, sleep/energy, and incontinence severity measures. The KHQ has been validated in a Korean version \[[@B24]\].

Subjects
--------

A total of 150 patients who visited the Department of Urology at Soonchunhyang University and provided informed consent were included in this study. Inclusion criteria were male ≥ 40 years of age, no history of prior treatment of BPH/LUTS, total IPSS ≥ 8, prostate volume \> 20 mL as determined by transrectal ultrasound, no relevant medical history, and underlying comorbidities. Exclusion criteria were history of neurogenic bladder dysfunction, history of prostate or bladder cancer, treatment history of acute or chronic urinary retention within the previous 3 months, treatment history of acute or chronic prostatitis within the previous 3 months, PSA levels \> 0.10 ng/mL, and history of urinary tract infection or bladder stones.

All patients were divided into 2 groups, non-obese (BMI \< 23 kg/m^**2**^) and obese (BMI ≥ 23 kg/m^2^), according to the Asia-Pacific obesity criteria \[[@B25]\]. For additional analysis, we also categorized patients into 2 groups based on waist circumference (WC), normal waist (≤90 cm) and central obesity (\>90 cm).

Power calculation
-----------------

Sample size was not calculated because its being a preliminary study.

Statistical analysis
--------------------

The primary outcome measurement was the degree of change of KHQ in the two groups, and secondary outcome measurement was the degree of change of IPSS in the two groups. All data are presented as mean ± SD. Statistical analysis was performed using SPSS (version 21.0; Chicago, IL, USA). Changes from baseline in total IPSS, QoL scores, and KHQ scores were analyzed using Wilcoxon signed-rank test. A P value \< 0.05 was considered significant.

Results
=======

Of the 140 enrolled patients, 96 completed the study. Fifty four patients discontinued the trial. Of these, 22 were lost to follow-up, 14 refused to complete the final questionnaires, and 18 patients discontinued the medication because of low efficacy (9 patients) or adverse events (9 patients) (Figure [1](#F1){ref-type="fig"}).

![Flow chart of enrolled patients.](1471-2490-14-60-1){#F1}

The basic characteristics, including age, PSA, PV, Qmax, total IPSS, and KHQ questionnaire are described in Table [1](#T1){ref-type="table"}. Between the obese group (BMI ≥ 23 kg/m^2^) and non-obese group (BMI \< 23 kg/m^2^), no significant difference occurred among the variables. Between the central obesity group (WC \> 90 cm) and non-central obesity group (WC ≤ 90 cm), no significant difference occurred among the variables except age.

###### 

Basic characteristics of participants

                           **BMI \< 23**   **BMI ≥ 23**    **P value**   **WC ≤ 90**     **WC \> 90**    **P value**
  ------------------------ --------------- --------------- ------------- --------------- --------------- -------------
  No                       21              75                            72              24               
  Age                      61.25±9.80      61.48±7.09      0.982         60.58±7.60      64.20±7.54      0.045
  PSA                      2.12±           2.04±           0.231         2.13±           1.98±           0.312
  PV                       31.12±10.14     34.23±8.71      0.042         32.31±9.81      33.23±10.21     0.218
  Qmax                     12.32±2.21      13.25±1.75      0.134         11.46±1.89      13.33±2.34      0.185
  IPSS questionnaire                                                                                     
  Total IPSS               14.90±7.58      13.41±6.79      0.388         15.00±7.57      13.31±6.74      0.308
  IPSS QoL                 3.47±1.21       3.54±1.22       0.830         3.56±1.40       3.51±1.15       0.864
  KHQ questionnaire                                                                                      
  General health           41.66±18.25     47.66±23.67     0.286         47.91±26.49     45.83±21.39     0.698
  Impact on life           53.91±30.65     58.60±30.40     0.534         58.27±28.20     57.35±31.22     0.898
  Role limitations         25.29±33.45     28.77±31.98     0.664         33.20±37.91     26.28±30.10     0.364
  Physical limitation      29.24±31.45     27.44±30.08     0.811         33.20±34.26     26.05±28.79     0.318
  Social limitation        22.19±31.81     16.71±25.48     0.411         18.03±24.83     17.87±27.59     0.980
  Personal relationships   21.71±37.96     25.39±32.24     0.724         24.90±35.34     24.55±32.84     0.972
  Emotions                 25.90±31.06     27.52±25.83     0.808         31.91±29.15     25.59±26.12     0.321
  Sleep/Energy             26.08±29.49     21.02±26.64     0.454         18.67±24.13     23.28±28.22     0.475
  Incontinence             14.14±27.47     9.85±14.73      0.343         16.50±21.31     8.89±16.76      0.076
  Total KHQ                251.88±223.71   254.88±171.03   0.947         274.31±198.90   247.53±178.02   0.537

After 8 weeks treatment with tamsulosin, overall improvement was seen in the total IPSS and IPSS QoL (P \< 0.001) (Table [2](#T2){ref-type="table"}). Total KHQ scores also improved after treatment (P \< 0.001). Among the domains, general health, impact on life, role limitations, physical limitation, emotions, sleep/energy, and incontinence severity were improved or significantly improved. However, social limitation and personal relationships did not show improvement after treatment (Table [2](#T2){ref-type="table"}).

###### 

Differences in IPSS and KHQ before and after treatment

                            **Mean difference**   **SD**    **95% CI**   **P value**  
  ------------------------ --------------------- --------- ------------ ------------- ----------
  IPSS                                                                                
  IPSS questionnaire               3.521           6.764      2.150         4.891      \< 0.001
  QoL                              1.011           1.487       .701         1.321      \< 0.001
  KHQ                                                                                 
  General health                  13.281          25.380      8.139        18.424      \< 0.001
  Impact on life                  18.417          32.513      11.829       25.004      \< 0.001
  Role limitations                10.302          26.954      4.841        15.764      \< 0.001
  Physical limitation              9.490          26.417      4.137        14.842       0.001
  Social limitation                3.323          24.418      -1.625        8.271       0.186
  Personal relationships           5.283          24.118      -1.365       11.931       0.117
  Emotions                         9.656          19.902      5.624        13.689      \< 0.001
  Sleep/Energy                     4.632          22.549       .038         9.225       0.048
  Incontinence                     3.010          14.141       .145         5.876       0.040
  Total KHQ                       76.167          144.346     46.920       105.414     \< 0.001

In subgroup analysis, the non-obese group showed no improvement in total KHQ (P = 0.055) (Table [3](#T3){ref-type="table"}). Among the KHQ domains, the obese group showed improvement only in general health (P = 0.025), impact on life (P = 0.020), and emotions (P = 0.047). The obese group showed improvement in total KHQ (P \< 0.001) (Table [3](#T3){ref-type="table"}). Among the KHQ domains, the obese group showed improvement in general health (P \< 0.001), impact on life (P \< 0.001), role limitations (P = 0.001), physical limitation (P \< 0.001), and emotions (P \< 0.001). The comparison of improvement of IPSS and KHQ revealed that obesity group showed significant greater improvement in total IPSS, physical limitation, and sleep/energy (Table [4](#T4){ref-type="table"}).

###### 

Differences in IPSS and KHQ before and after treatment according to BMI

                            **BMI \< 23**   **BMI ≥ 23**                            
  ------------------------ --------------- -------------- ------ -------- --------- ----------
  IPSS questionnaire                                                                
  Total IPSS                    5.571          7.928       .004   2.947     6.341    \< 0.001
  QoL                           1.105          1.243       .001    .986     1.552    \< 0.001
  KHQ questionnaire                                                                 
  General health               10.714          20.266      .025   14.000   26.712    \< 0.001
  Impact on life               20.619          37.377      .020   17.800   31.269    \< 0.001
  Role limitations              9.381          27.006      .127   10.560   27.116     0.001
  Physical limitation           3.190          34.945      .680   11.253   23.483    \< 0.001
  Social limitation             8.429          27.770      .180   1.893    23.400     0.486
  Personal relationships        5.556          37.250      .666   5.227    21.101     0.108
  Emotions                     10.571          22.892      .047   9.400    19.146    \< 0.001
  Sleep/Energy                  7.048          25.488      .220   3.946    21.785      .124
  Incontinence                  6.524          23.159      .211   2.027    10.357      .094
  Total KHQ                    79.762         179.641      .055   75.160   134.246   \< 0.001

###### 

Differences in IPSS and KHQ before and after treatment according to waist circumference

                            **WC \< 90**   **WC ≥ 90**                            
  ------------------------ -------------- ------------- ------ -------- --------- ----------
  IPSS questionnaire                                                              
  Total IPSS                   2.667          7.191      .082   3.806     6.643    \< 0.001
  QoL                           .957          1.637      .010   1.029     1.445    \< 0.001
  KHQ questionnaire                                                               
  General health               14.583        28.473      .020   12.847   24.464    \< 0.001
  Impact on life               15.292        32.742      .032   19.458   32.600    \< 0.001
  Role limitations             8.250         38.649      .307   10.986   22.053    \< 0.001
  Physical limitation          8.333         28.448      .165   9.875    25.904     0.002
  Social limitation             .083         20.581      .984   4.403    25.610     0.149
  Personal relationships       -4.714        21.084      .418   8.872    24.369     0.029
  Emotions                     3.667         18.253      .335   11.653   20.147    \< 0.001
  Sleep/Energy                 -1.458        14.623      .630   6.690    24.404     0.024
  Incontinence                 3.000         12.487      .251   3.014    14.733     0.087
  Total KHQ                    52.333        165.817     .136   84.111   136.806   \< 0.001

In other subgroup analysis, the non-central obesity group showed no improvement in total IPSS, IPSS QoL, and total KHQ (Table [4](#T4){ref-type="table"}). Among the KHQ domains, the non-central obesity group showed improvement only in general health (P = 0.020) and impact on life (P = 0.032). The central obesity group showed improvement in total IPSS, IPSS QoL, and total KHQ (Table [5](#T5){ref-type="table"}). Among the KHQ domains, the central obesity group showed improvement in general health P \< 0.001), impact on life (P \< 0.001), role limitations (P \< 0.001), physical limitation (P = 0.002), personal relationships (P = 0.029), emotions (P \< 0.001), and sleep/energy (P = 0.024). The comparison of improvement of IPSS and KHQ revealed that central obesity group showed significant greater improvement in total IPSS, impact of life, and sleep/energy (Table [5](#T5){ref-type="table"}).

###### 

Comparison of the differences in IPSS and KHQ according to BMI and waist circumference

                            **BMI \< 23**   **BMI ≥ 23**   **P value**   **WC ≤ 90**    **WC \> 90**   **P value**
  ------------------------- --------------- -------------- ------------- -------------- -------------- -------------
  IPSS questionnaire                                                                                   
  ∆Total IPSS               3.37±6.17       6.00±7.66      0.041         2.87±7.18      4.30±6.38      0.028
  ∆IPSS QoL                 0.96±1.52       1.00±1.22      0.830         0.79±1.79      1.02±1.34      0.231
  KHQ questionnaire                                                                                    
  ∆General health           10.71±20.26     14.00±26.71    0.286         14.58±28.47    12.84±24.46    0.321
  ∆Impact on life           17.76±31.12     20.06±37.19    0.052         15.26±32.53    19.42±32.46    0.028
  ∆Role limitations         10.61±27.10     9.48±27.05     0.564         8.30±38.54     11.06±22.11    0.356
  ∆Physical limitation      3.16±35.06      11.28±23.50    0.032         8.30±28.54     9.91±25.93     0.068
  ∆Social limitation        4.20±22.84      3.16±27.08     0.347         4.01±20.62     4.39±25.64     0.780
  ∆Personal relationships   5.71±27.96      5.39±22.24     0.561         5.09±22.05     4.71±28.32     0.814
  ∆Emotions                 9.47±19.19      10.57±22.87    0.706         10.91±18.41    11.76±20.14    0.415
  ∆Sleep/Energy             3.98±21.63      7.11±25.48     0.031         3.21±14.61     6.68±24.23     0.035
  ∆Incontinence             19.69±24.66     18.35±24.96    0.381         18.43±24.99    19.72±24.64    0.451
  ∆Total KHQ                75.20±134.25    79.87±179.59   0.061         52.47±165.90   84.14±136.77   0.071

Adverse events were reported in 9 patients (6.0%) and included dizziness (3.3%), postural hypotension (1.3%), and gastric discomfort (1.3%).

Discussion
==========

When obese patients with BPH have LUTS, a larger prostate is presumed to be one of the causes. The prostate grows faster in obese than in non-obese patients \[[@B26]-[@B28]\].

Many clinical studies have focused on prostate size or PSA in obese patients, but few studies have focused on the treatment outcome, including QoL, in obese patients. Although several studies have used the IPSS-QoL index to present the treatment outcome in obese patients \[[@B14],[@B29],[@B30]\], the IPSS-QoL is not a disease-specific questionnaire. Rather, it represents the state of generalized HRQoL in men with LUTS.

The most prominent feature of our study was use of the KHQ questionnaire, a disease-specific HRQoL instrument for the evaluation of patients with LUTS, overactive bladder, and urinary incontinence \[[@B9],[@B16]-[@B19]\]. The KHQ consists of nine domains. Seven of the domains include multiple questions including role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy, and incontinence severity measures.

Our study revealed that comparison of improvement of IPSS QoL according to BMI and WC showed no significant difference. However, the comparison of improvement KHQ including impact on life, physical limitation, impact of life, and sleep/energy showed significant difference. Although improvement of total KHQ showed no significant difference, several domains of KHQ showed significant differences.

Although some controversies exist regarding the relationship between the severity of LUTS and obesity, obese patients usually have more severe LUTS than non-obese patients \[[@B29],[@B30]\]. Possible reasons for this phenomenon are lower testosterone concentrations, lower serum globulin-binding protein levels, and greater prostate volumes in obese patients \[[@B31]\], as well as increased estrogen levels and increased free and total estradiol concentrations \[[@B32],[@B33]\].

Our data demonstrate that the baseline total IPSS showed no significant difference between the obese and non-obese groups or central obesity and non-central obesity groups. This is mainly due to our lower IPSS inclusion criteria of more than 8 points total on the IPSS. We lowered the criteria for the IPSS because patients scoring higher on the IPSS could bias the results by showing more satisfaction with treatment.

Our data showed a more favorable treatment outcome in obese patients and those with central obesity. Although an improvement in the total IPSS was demonstrated in both obese and non-obese patients, the improvement in the total IPSS was only demonstrated in patients with central obesity. Improvement in total KHQ scores was demonstrated only in obese patients and patients with central obesity.

Greater estrogen levels in old age and obesity induce lower testosterone levels and may affect prostate cell growth \[[@B32]\]. Enlarged adipose tissue can secrete numerous hormones and proteins that influence fat metabolism \[[@B34],[@B35]\], and leptin stimulates the cellular proliferation of BPH \[[@B36],[@B37]\].

Besides an enlarged prostate, obese patients have increased sympathetic tone, which is suspected to be the main reason alpha blockers could have a greater impact in obese patients. Increased sympathetic tone can result in LUTS and subjective voiding complaints \[[@B19]\]. In particular, abdominal obesity increases the estrogen-to-androgen ratio and may increase sympathetic nervous system activity, both of which are known to influence the development of BPH and the severity of LUTS \[[@B18]\]. In our study, obese patients showed improvement in 5 domains of the KHQ, but central obesity patients showed improvement in 7 domains of the KHQ. This result implies that obesity, especially central obesity, which is regarded as visceral obesity, could impact treatment outcomes. The main reason for this result is that obesity, and especially visceral adiposity, is closely related to sympathetic overactivity \[[@B38],[@B39]\]. The whole body norepinephrine spillover rate is known to be quantitatively linked with waist circumference \[[@B17],[@B31]\], and sympathetic nerve firing rates measured by microneurography have been reported to be 55% higher in men with visceral adiposity than in men with only subcutaneous obesity.

Sympathetic activity is increased in obese men and may be related to BPH/LUTS by a common link between norepinephrine and alpha-1 adrenoceptors \[[@B38],[@B39]\]. Although general improvement of LUTS and KHQ were observed in this study, the obesity and central obesity groups showed more improvement in the IPSS and KHQ.

This study has several limitations. First, the study design has a relatively short follow-up period. However, 8 weeks is sufficient to judge the clinical outcome of alpha blockers. Moreover, the KHQ is a relatively long questionnaire and takes a long time to perform, which reduces patient compliance. Although the acquisition of questionnaire was performed by one special interviewer, a lot of patients showed negative response to the KHQ in our study. The most common reason for this negative response is that it takes quite a long time. This is why we did not perform an additional KHQ at 4 weeks. Second, this study has a relatively small size. However, considering the increasing prevalence of concomitant medical diseases, the availability of eligible patients is limited. This was a pilot; a preliminary study, and subsequent prospective study is needed.

Conclusions
===========

Obese or central obesity patients with LUTS showed a better health-related quality of life than non-obese or non-centrally obese patients with LUTS after alpha-adrenergic medication. Therefore, alpha-adrenergic medication can be recommended to obese patients with LUTS preferentially for the improvement of quality of life.
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